Secretome Doses First Patient in Landmark Stem Cell Trial for Heart Failure
Secretome Therapeutics, a clinical-stage biotechnology company developing innovative therapies from neonatal cardiac progenitor cells (nCPCs), announced today that the first patient has been dosed in its Phase 1 clinical trial of STM-01 for heart failure with preserved ejection fraction (HFpEF). This marks the first-ever clinical study of an allogeneic, off-the-shelf stem cell therapy for HFpEF, a leading global cause of hospitalization, morbidity, and mortality. In the U.S. alone, approximately 6.7 million adults live with heart failure, with HFpEF accounting for at least half of these cases.
Secretome Doses First Patient in Landmark Stem Cell Trial for Heart Failure